|
Academic Title |
Associate Professor
Chief, Division of Endocrinology and Molecular Medicine |
 |
|
Departmental Affiliation |
Internal Medicine |
|
Mailing Address |
UK Medical Center
MN524
Lexington, KY
40536-0298
|
|
Office/Lab |
Wethington Building,
room 567 |
|
Telephone |
(859) 323-5821 |
|
Fax |
(859) 323-5707 |
|
E-mail |
Lisa.Tannock@uky.edu |
Clinical Interests
Dr. Lisa Tannock has special
interests in hyperlipidemia,
diabetic dyslipidemia, metabolic syndrome, and
lipodystrophy. She received her
medical degree and completed a residency at the University of
Toronto, Ontario, Canada. Dr.
Tannock completed a fellowship at the University
of Washington, Seattle,
Washington.
Internal Medicine
She is board certified in
internal medicine and
endocrinology and is a Fellow of
the American Heart Association. To
refer a patient to Dr. Tannock,
call UK·MDs at
(800) 888-5533
or in Lexington,
call
(859) 231-9922.
Research/Clinical
Interests
Cardiovascular disease
remains the primary
cause of morbidity and
mortality in developed
countries. Although
cardiovascular death
rates have declined in
recent years, likely due
to increased prevention
and improved medical
care, the death rates
have not dropped as
dramatically in men with
diabetes, and have
actually increased in
women with diabetes.
Thus, therapies which
reduce atherosclerosis,
particularly in the
diabetic population, are
urgently needed.
Proteoglycans have been
shown to play a critical
role in the initiation
of atherosclerosis due
to their ability to bind
atherogenic lipoproteins
leading to retention in
the artery wall, as
outlined in the
"response to retention
hypothesis".
The goal of
this laboratory is to
identify modifications
of proteoglycans that
may be atheroprotective.
A major focus of the lab
is to identify the
underlying mechanisms
leading to the reduced
proteoglycan-lipoprotein
interactions, and to
understand the
regulation of
proteoglycan synthesis.
Diabetic nephropathy
occurs in 30% of
individuals with type 1,
and 10% of individuals
with type 2 diabetes.
Diabetic nephropathy is
characterized by
mesangial cell injury
and progressive
accumulation of
mesangial matrix and
proteoglycans. Lipids
and lipoproteins have
been shown to accumulate
in the glomerulus and
are thought to play a
role in the pathogenesis
of renal injury.
Proteoglycans, which
play a key role in the
development of
atherosclerosis due to
their ability to bind
and retain lipoproteins
in the artery wall, may
also contribute to
lipoprotein retention in
the glomerulus.
An
additional focus of this
laboratory is to test
the hypothesis that
lipoprotein retention is
a key step in the
pathogenesis of
nephropathy. Thus, we
are interested in
comparing the effects of
factors shown to modify
lipoprotein retention by vascular proteoglycans with their
effects on lipoprotein
retention by mesangial proteoglycans. Mouse
models are used to
evaluate the relative
contributions of
hyperglycemia and
hyperlipidemia on the
development of diabetic
atherosclerosis and
glomerulosclerosis in
vivo. |
